Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer

B. E. P. J. Vriens, I. J. H. Vriens, M. J. B. Aarts, S. M. van Gastel, F. W. P. J. van den Berkmortel, T. J. Smilde, L. J. C. van Warmerdam, D. J. van Spronsen, P. G. M. Peer, M. de Boer, V. C. G. Tjan-Heijnen*, Breast Canc Trialists Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)593-600
Number of pages8
JournalBreast Cancer Research and Treatment
Volume165
Issue number3
DOIs
Publication statusPublished - Oct 2017

Keywords

  • Breast cancer
  • Neoadjuvant chemotherapy
  • Disease-free survival
  • Overall survival
  • SURGICAL ADJUVANT BREAST
  • CELL-DEATH
  • PHASE-III
  • DOCETAXEL
  • DOXORUBICIN
  • TRIAL
  • DOXORUBICIN/CYCLOPHOSPHAMIDE
  • CYCLOPHOSPHAMIDE
  • ANTHRACYCLINE
  • THERAPY

Cite this